Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17094558 | 0.70 | KDM6B (0.44) | ALDH1A1HTTL3MBTL1LMNA | |
| SCHEMBL17094094 | 0.69 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL16616069 | 0.69 | MEN1 (0.40) | ALDH1A1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL16615978 | 0.67 | MEN1 (0.36) | ALDH1A1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL2574651 | 0.66 | MEN1 (0.33) | ALDH1A1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL17467133 | 0.65 | AGBL2 (0.38) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL671737 | 0.65 | TDP1 (0.32) | ALDH1A1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL8773482 | 0.63 | MEN1 (0.69) | ALDH1A1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL25244288 | 0.63 | MEN1 (0.33) | ALDH1A1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL16403091 | 0.63 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2AHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | ALDH1A1 431/4885MEN1 1714/4885KMT2A 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.